The effect of moderate‐dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double‐blind, placebo‐controlled trial
- 30 October 2006
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 54 (11), 3623-3632
- https://doi.org/10.1002/art.22198
Abstract
Objective Serial measurements of anti–double‐stranded DNA (anti‐dsDNA) and complement are routine in the management of systemic lupus erythematosus (SLE), but their utility as biomarkers in preemptive treatment to prevent flares remains a subject of controversy. We hypothesized that concomitant elevation of anti‐dsDNA and C3a can predict SLE activity in patients with stable or inactive disease and that short‐term treatment with corticosteroids can avert flares. Methods In this prospective, randomized, double‐blind, placebo‐controlled trial, 154 patients were evaluated monthly for up to 18 months, with measurements of C3a, C3, C4, CH50, and anti‐dsDNA levels. Patients who remained clinically stable but showed serologic evidence of an SLE flare (elevation of both the anti‐dsDNA level by 25% and the C3a level by 50% over the previous 1–2 monthly visits) were randomized to receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week, and 10 mg/day for 1 week. Results Forty‐one patients (21 randomized to prednisone and 20 randomized to placebo) experienced a serologic flare. Analysis of severe flares occurring ≤90 days from randomization revealed that 6 occurred in patients taking placebo and none occurred in patients taking prednisone (P = 0.007). Severe flares resulted in an increase in the prednisone dosage to >40 mg/day and/or the addition of an immunosuppressive agent. Furthermore, improvement in scores on the Systemic Lupus Erythematosus Disease Activity Index, decreased levels of anti‐dsDNA antibodies, and increased levels of C4 occurred 1 month after initiation of prednisone treatment. Conclusion These preliminary data support our hypothesis that in a subset of clinically stable SLE patients with a combination of elevated C3a and anti‐dsDNA levels, short‐term corticosteroid therapy may avert a severe flare.Keywords
This publication has 38 references indexed in Scilit:
- The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized TrialAnnals of Internal Medicine, 2005
- Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective studyRheumatology, 2004
- Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests failArthritis & Rheumatism, 1996
- Prevention of relapses in systemic lupus erythematosusThe Lancet, 1995
- Outcome of Systemic Lupus Erythematosus a Study of 66 Patients over 7 Years with Special Reference to the Predictive Value of Anti-DNA Antibody DeterminationsScandinavian Journal of Rheumatology, 1991
- Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosusArthritis & Rheumatism, 1990
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982
- Serologically active clinically quiescent systemic lupus erythematosusAmerican Journal Of Medicine, 1979
- Immunologic Factors and Clinical Activity in Systemic Lupus ErythematosusNew England Journal of Medicine, 1968